Intelligence · Clinical pipeline
Oncology R&D Pipeline
Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.
Quick answer
Oncology: NovaPharmaNews indexes 33 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.
Top sponsors
- First People's Hospital 474 programs
- Chinese Academy of 400 programs
- United Therapeutics Europe 219 programs
- George Institute for 172 programs
- Takeda 163 programs
- HOFFMANN-LA ROCHE 144 programs
- AstraZeneca 143 programs
- MSD Merck Sharp 131 programs
- Regeneron UK 128 programs
- Anaxis Pharma 125 programs
- Telethon Foundation 113 programs
- Novartis India 110 programs
Pipeline programs
-
INCB 54828-302
Incyte
Cholangiocarcinoma
1 trial -
asparaginase
United Therapeutics Europe Ltd
Lymphoma
1 trial -
filgrastim
Solid Biosciences
Lymphoma
2 trials -
recombinant human erythropoietin
The First People's Hospital of Lianyungang
Lymphoma
1 trial -
68Ga-FAP-CHX
The First People's Hospital of Lianyungang
Tumor
1 trial -
Bendamustine
Adaptive Biotechnologies Corp
Lymphoma
1 trial -
E7090
Eisai Co.,
Cholangiocarcinoma
1 trial -
IOV-COM-202
Iovance Biotherapeutics B.V.
Neoplasm
1 trial -
Ibrutinib
Karyopharm Therapeutics Inc
Lymphoma
1 trial -
Iparomlimab and Tuvonralimab Injection (QL1706)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Cholangiocarcinoma
1 trial -
Lenvatinib
Eisai Co.,
Osteosarcoma
1 trial -
Linperlisib combination with obinutuzumab
The First People's Hospital of Lianyungang
Lymphoma
1 trial -
Mifamurtide
Takeda
Osteosarcoma
1 trial -
NKTR-102 100 mg/m2
Nektar Therapeutics UK Limited
Tumor
1 trial -
NKTR-102 q14d
Nektar Therapeutics UK Limited
Tumor
1 trial -
Parsaclisib
Incyte
Lymphoma
1 trial -
REOLYSIN®
ONCOLYTICS BIOTECH INC
Osteosarcoma
1 trial -
Trilaciclib
The First People's Hospital of Lianyungang
Osteosarcoma
1 trial -
Umbralisib
TG THERAPEUTICS, INC.
Lymphoma
1 trial -
certepetide
LISATA THERAPEUTICS, INC.
Cholangiocarcinoma
1 trial -
forodesine hydrochloride
Biocryst
Lymphoma
2 trials -
fostamatinib
RIGEL PHARMACEUTICALS INC
Lymphoma
1 trial -
rituximab
United Therapeutics Europe Ltd
Lymphoma
1 trial -
2018-523-00US1
Hutchmed Europe B.V.
Lymphoma
1 trial -
68Ga-FAPI-Biotin
The First People's Hospital of Lianyungang
Tumor
1 trial -
68Ga-Pentixafor
The First People's Hospital of Lianyungang
Lymphoma
1 trial -
Azenosertib
Zentalis Pharmaceuticals
Osteosarcoma
1 trial -
Recombinant oncolytic herpes simplex virus type Ⅰ (R130)
Shanghai University of Traditional Chinese Medicine
Osteosarcoma
1 trial -
Selinexor
Karyopharm Therapeutics Inc
Liposarcoma
1 trial -
The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T)
Sinobioway Cell Therapy Co.,
Lymphoma
1 trial -
ziv-aflibercept
Regeneron UK Limited
Lymphoma
2 trials -
Brentuximab vedotin
Takeda
Lymphoma
2 trials -
XMYY-2024KY024
The First People's Hospital of Lianyungang
Tumor
1 trial
Frequently asked questions
How many oncology pipeline programs are tracked?
33 programs match this therapeutic area based on indication text, program name, and registry metadata.
Where does pipeline data come from?
ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.